Will Aphria (TSX:APHA) Stock Hit Double Digits This Winter?

Aphria Inc. (TSX:APHA)(NYSE:APHA) disappointed in Q2 but is still one of the most profitable pot companies.

edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Aphria (TSX:APHA)(NYSE:APHA) stock is currently trading around $7, far from its 52-week high of $14.37, which was reached on February 4, 2019. The last time Aphria’s share price was in the double digits was on August 6, when the stock traded at a high of $10.05. Like other cannabis stocks, Aphria stock fell in 2019, plunging 11% over the year.

However, it fell less than other big pot companies. In comparison, Canopy Growth plunged by 24%. 

Let’s see if Aphria’s stock has what it takes to hit double digits this winter.

Aphria’s second-quarter earnings disappoint

On January 14, Aphria’s share price fell 9% at the start of trading after the company missed second-quarter revenue estimates and cut its forecast for the whole year. The stock has gained back about 8% of its value since then. 

Aphria reported net revenue of $120.6 million — an increase of 457% over the same period last year but a sequential decline from the $126.1 million reported in the previous quarter. Analysts expected Aphria to report revenue of $130.4 million.

Sales from the company’s German pharmaceutical distribution business fell, while the quantity of cannabis sold on the Canadian recreational market slightly improved.

The pot giant also reported cannabis revenues of $33.7 million during the quarter, selling 5,567 kilograms, up from $30.8 million but below the 5,969 kilograms sold during the previous quarter.

Aphria reported a net loss of $7.9 million in the second quarter of fiscal 2020 compared to a gain of $54.8 million for the same period last year. Analysts expected the company to report a net loss of $9.7 million. 

Aphria could be the first pot company to pay dividends to shareholders. Indeed, CFO Carl Melton said that Aphria would like to return money to shareholders.

The Canadian pot producer has posted three consecutive quarters of positive adjusted EBITDA, a rarity in the industry, and aims to continue this trend “to both internally finance future growth initiatives and, in the future, being in the position to provide an annual return to our shareholders through dividends,” said Merton.

While Aphria stands out for its profitability, the numbers are small, with adjusted second-quarter EBITDA standing at $1.9 million. But this is an improvement compared to the loss of $9.5 million it reported a year earlier. At the end of the quarter, the company had close to $500 million in cash.

Aphria has adjusted its forecast for fiscal year 2020. Projected revenues are expected to be in the range of $575 million to $625 million, down from the $650 million to $700 million the company previously forecasted.

The company said the decline in expected revenue for the year is due to slower-than-expected store openings in Ontario, a temporary ban on vaping products in Alberta, and slower growth of its pharmaceutical distribution activities in Germany.

The company forecasts adjusted EBITDA of approximately $35 million to $42 million, down from previous forecasts of $8 million to $95 million.

The company plans to add 34 new vaping products to its portfolio and hopes to launch a new portfolio of edible cannabis-infused products in the next two quarters.

Analysts, on average, expect Aphria’s fiscal 2022 EPS to be $0.40.

Aphria stock should perform better in 2020

Aphria’s shares have been beaten up lately because the company’s fiscal 2020 second-quarter report didn’t meet analyst expectations. 

But if you look more closely at the results, trends are actually pretty good. Aphria’s quarter-over-quarter cannabis revenue and cannabis volume growth have accelerated compared to Q1 rates. These numbers imply that the demand for cannabis from Aphria is increasing.

In addition, the company’s strong Canadian medical marijuana activity combined with a strong brand image for its recreational product as well as the potential of a constantly expanding U.S. business place Aphria in a privileged position to benefit from cannabis in 2020.

So, the stock should rally in 2020. I believe that it will hit double digits sometimes this year, but the chances that it will happen this winter are small.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »